SEC Form 4 · accession 0001209191-16-137770
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Aug 17, 2016
Accepted (ET)
Aug 18, 2016 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 17, 2016 | M | 6,500 | $36.30 | A | 274,725 | D | |
| Common StockF2,F3 | Aug 17, 2016 | S | 4,000 | $99.36 | D | 270,725 | D | |
| Common StockF2,F4 | Aug 17, 2016 | S | 2,500 | $99.99 | D | 268,225 | D | |
| Common StockF2,F5 | Aug 17, 2016 | S | 400 | $100.03 | D | 80,300 | I | Common Stock Held In Trust |
| Common Stock | holding | — | — | — | 13,286 | I | 401k |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $36.30 | Aug 17, 2016 | M | 6,500 | D | — | Jan 23, 2017 | Common Stock | 6,500 | 138,000 | D |
Explanation of responses
- F1Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1.
- F2The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $99.36 (range $98.87 to $99.84).
- F4Open market sales reported on this line occurred at a weighted average price of $99.99 (range $99.91 to $100.12).
- F5Open market sales reported on this line occurred at a weighted average price of $100.03 (range $100.00 to $100.08).
- F6Fully vested.